| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528702 | Current Opinion in Pharmacology | 2017 | 7 Pages |
Abstract
Bile acids are central signals in enterohepatic communication and also integrate microbiota-derived signals into this signaling axis. Discovery of the tissue distribution and signaling pathways activated by the natural receptors for bile acids, farnesoid X receptor and G protein-coupled bile acid receptor 1 (GPBAR1) also known as TGR5, and bile acid transporters has led to the development of therapeutic agents that target these molecules. Obeticholic acid, a selective FXR agonist, and NGM282, a non-mitogenic FGF-19 analog, are two of the agents in this pipeline. Obeticholic acid has been approved by regulatory agencies for use in patients with primary biliary cholangitis.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Harmeet Malhi, Michael Camilleri,